Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Oct;66(4):765–769. doi: 10.1038/bjc.1992.353

Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests.

C J Twelves 1, N A Dobbs 1, Y Michael 1, L A Summers 1, W Gregory 1, P G Harper 1, R D Rubens 1, M A Richards 1
PMCID: PMC1977407  PMID: 1419619

Abstract

The influence of liver biochemistry tests on epirubicin pharmacokinetics has been investigated in 52 women with advanced breast cancer, 27 of whom had radiologically proven liver metastases. Patients received epirubicin 12.5-120 mg m-2 given as an i.v. bolus. Epirubicin levels were measured by HPLC following the first cycle of treatment. Epirubicin elimination, expressed as clearance (dose/AUC), in the 22 patients with normal AST and bilirubin was compared with that of 30 patients with a raised AST +/- raised bilirubin. Epirubicin clearance was significantly reduced in the patients with a raised AST, whether their serum bilirubin was normal (22 patients) or elevated (eight patients). In the 30 patients with a raised AST +/- raised bilirubin, epirubicin clearance correlated strongly with the level of AST (r = -0.72) but not with serum bilirubin, alkaline phosphatase, albumin or creatinine. Using a multiple regression analysis, AST was the only one of these biochemical variables predictive of epirubicin clearance (r2 = 0.47, P = 0.0006). We conclude that a raised serum AST is a more sensitive and reliable measure of abnormal epirubicin pharmacokinetics than increased bilirubin. These findings have implications for anthracycline treatment in patients with abnormal liver biochemistry.

Full text

PDF
765

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benjamin R. S., Wiernik P. H., Bachur N. R. Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer. 1974 Jan;33(1):19–27. doi: 10.1002/1097-0142(197401)33:1<19::aid-cncr2820330107>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  2. Brambilla C., Rossi A., Bonfante V., Ferrari L., Villani F., Crippa F., Bonadonna G. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep. 1986 Feb;70(2):261–266. [PubMed] [Google Scholar]
  3. Brenner D. E., Wiernik P. H., Wesley M., Bachur N. R. Acute doxorubicin toxicity. Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia. Cancer. 1984 Mar 1;53(5):1042–1048. doi: 10.1002/1097-0142(19840301)53:5<1042::aid-cncr2820530505>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  4. Camaggi C. M., Comparsi R., Strocchi E., Testoni F., Angelelli B., Pannuti F. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer Chemother Pharmacol. 1988;21(3):221–228. doi: 10.1007/BF00262774. [DOI] [PubMed] [Google Scholar]
  5. Camaggi C. M., Strocchi E., Comparsi R., Testoni F., Angelelli B., Pannuti F. Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients. Cancer Chemother Pharmacol. 1986;18(1):47–50. doi: 10.1007/BF00253063. [DOI] [PubMed] [Google Scholar]
  6. Camaggi C. M., Strocchi E., Tamassia V., Martoni A., Giovannini M., Lafelice G., Canova N., Marraro D., Martini A., Pannuti F. Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases. Cancer Treat Rep. 1982 Oct;66(10):1819–1824. [PubMed] [Google Scholar]
  7. Carmo-Pereira J., Costa F. O., Miles D. W., Henriques E., Richards M. A., Rubens R. D. High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study. Cancer Chemother Pharmacol. 1991;27(5):394–396. doi: 10.1007/BF00688864. [DOI] [PubMed] [Google Scholar]
  8. Dobbs N. A., Twelves C. J. Measurement of epidoxorubicin and its metabolites by high-performance liquid chromatography using an advanced automated sample processor. J Chromatogr. 1991 Dec 6;572(1-2):211–217. doi: 10.1016/0378-4347(91)80485-u. [DOI] [PubMed] [Google Scholar]
  9. Frenay M., Milano G., Renee N., Pons D., Khater R., François E., Thyss A., Namer M. Pharmacokinetics of weekly low dose doxorubicin. Eur J Cancer Clin Oncol. 1989 Feb;25(2):191–195. doi: 10.1016/0277-5379(89)90007-2. [DOI] [PubMed] [Google Scholar]
  10. Hoyumpa A. M., Schenker S. Is glucuronidation truly preserved in patients with liver disease? Hepatology. 1991 Apr;13(4):786–795. [PubMed] [Google Scholar]
  11. Johnston A., Woollard R. C. STRIPE: an interactive computer program for the analysis of drug pharmacokinetics. J Pharmacol Methods. 1983 May;9(3):193–199. doi: 10.1016/0160-5402(83)90038-4. [DOI] [PubMed] [Google Scholar]
  12. Maessen P. A., Mross K. B., Pinedo H. M., van der Vijgh W. J. Metabolism of epidoxorubicin in animals: absence of glucuronidation. Cancer Chemother Pharmacol. 1987;20(1):85–87. doi: 10.1007/BF00252968. [DOI] [PubMed] [Google Scholar]
  13. Mross K., Maessen P., van der Vijgh W. J., Gall H., Boven E., Pinedo H. M. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol. 1988 Mar;6(3):517–526. doi: 10.1200/JCO.1988.6.3.517. [DOI] [PubMed] [Google Scholar]
  14. O'Reilly S. M., Richards M. A., Rubens R. D. Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival. Eur J Cancer. 1990;26(5):574–577. doi: 10.1016/0277-5379(90)90080-d. [DOI] [PubMed] [Google Scholar]
  15. Perrier D., Gibaldi M. Clearance and biologic half-life as indices of intrinsic hepatic metabolism. J Pharmacol Exp Ther. 1974 Oct;191(1):17–24. [PubMed] [Google Scholar]
  16. Preisler H. D., Gessner T., Azarnia N., Bolanowska W., Epstein J., Early A. P., D'Arrigo P., Vogler R., Winton L., Chervenik P. Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemother Pharmacol. 1984;12(2):125–130. doi: 10.1007/BF00254604. [DOI] [PubMed] [Google Scholar]
  17. Preiss R., Matthias M., Sohr R., Brockmann B., Hüller H. Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver. J Cancer Res Clin Oncol. 1987;113(6):593–598. doi: 10.1007/BF00390872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Robert J., David M., Granger C. Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug. Cancer Chemother Pharmacol. 1990;27(2):147–150. doi: 10.1007/BF00689100. [DOI] [PubMed] [Google Scholar]
  19. Robert J., Hoerni B., Vrignaud P., Lagarde C. Early-phase pharmacokinetics of doxorubicin in non-Hodgkin lymphoma patients. Dose-dependent and time-dependent pharmacokinetic parameters. Cancer Chemother Pharmacol. 1983;10(2):115–119. doi: 10.1007/BF00446222. [DOI] [PubMed] [Google Scholar]
  20. Robert J., Vrignaud P., Nguyen-Ngoc T., Iliadis A., Mauriac L., Hurteloup P. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. Cancer Treat Rep. 1985 Jun;69(6):633–640. [PubMed] [Google Scholar]
  21. Robinson M. H., Jones A. C., Durrant K. D. Effectiveness of scalp cooling in reducing alopecia caused by epirubicin treatment of advanced breast cancer. Cancer Treat Rep. 1987 Oct;71(10):913–914. [PubMed] [Google Scholar]
  22. Speth P. A., Linssen P. C., Beex L. V., Boezeman J. B., Haanen C. Cellular and plasma pharmacokinetics of weekly 20-mg 4'-epi-adriamycin bolus injection in patients with advanced breast carcinoma. Cancer Chemother Pharmacol. 1986;18(1):78–82. doi: 10.1007/BF00253070. [DOI] [PubMed] [Google Scholar]
  23. Twelves C. J., Richards M. A., Smith P., Rubens R. D. Epirubicin in breast cancer patients with liver metastases and abnormal liver biochemistry: initial weekly treatment followed by rescheduling and intensification. Ann Oncol. 1991 Oct;2(9):663–666. doi: 10.1093/oxfordjournals.annonc.a058045. [DOI] [PubMed] [Google Scholar]
  24. Weenen H., Lankelma J., Penders P. G., McVie J. G., ten Bokkel Huinink W. W., de Planque M. M., Pinedo H. M. Pharmacokinetics of 4'-epi-doxorubicin in man. Invest New Drugs. 1983;1(1):59–64. doi: 10.1007/BF00180192. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES